Cilostazol is known to be a selective inhibitor of phosphodiesterase III and is generally used to treat stroke. Our previous findings showed that cilostazol enhanced capillary density through angiogenesis after focal cerebral ischemia. Angiogenesis is an important physiological process for promoting revascularization to overcome tissue ischemia. It is a multistep process consisting of endothelial cell proliferation, migration, and tubular structure formation. Here, we examined the modulatory effect of cilostazol at each step of the angiogenic mechanism by using human brain microvascular endothelial cells (HBMECs). We found that cilostazol increased the migration of HBMECs in a dose-dependent manner. However, it did not enhance HBMEC proliferation and capillary-like tube formation. We used a cDNA microarray to analyze the mechanisms of cilostazol in cell migration. We picked five candidate genes that were potentially related to cell migration, and we confirmed the gene expression levels by real-time PCR. The genes phosphoserine aminotransferase 1 (PSAT1) and CCAAT/enhancer binding protein β (C/EBPβ) were up-regulated. The genes tissue factor pathway inhibitor 2 (TFPI2), retinoic acid receptor responder 1 (RARRES1), and RARRES3 were down-regulated. Our observations suggest that cilostazol can promote angiogenesis by promoting endothelial migration. Understanding the cilostazol-modulated regulatory mechanisms in brain endothelial cells may help stimulate blood vessel formation for the treatment of ischemic diseases.
Introduction
Angiogenesis is the formation of new blood vessels from pre-existing vessels, and is a multistep process consisting of endothelial cell proliferation, migration, and tubular structure formation [1, 4] . When quiescent endothelial cells are activated by various stimuli, activated endothelial cells degrade extracellular matrix, proliferate, and migrate to the site of stimuli. Angiogenesis is completed by the formation and organization of a new lumen, namely, in a tube structure.
Angiogenesis is involved in embryonic vasculature formation and is a central process in cancer progression, which means that tumor growth can be effectively inhibited by anti-angiogenic therapy [1, 5] . Conversely, angiogenesis is also an important physiological process for promoting revascularization to overcome tissue ischemia. Vascular endothelial growth factor (VEGF) restores ischemic renal injury through angiogenesis [20] . Pioglitazone promotes blood flow recovery and capillary density through VEGF upregulation [2] .
Administration of plant extract in cases of ischemic stroke reduced infarct damage and enhanced angiogenesis via the angiogenic factors VEGF and angiopoietin-1 and 2 [6] . In addition, the transplantation of bone marrow mononuclear cells into ischemic myocardium augmented collateral vessel formation and improved functional outcome [11] . Implantation of peripheral mononuclear cells into ischemic hindlimb prevented limb amputation by inducing neovascularization [35] . Therefore, therapeutic angiogenesis holds promise for treatment of ischemic diseases.
Cilostazol, a selective type III phosphodiesterase inhibitor, is known to be an anti-platelet agent with vasodilatory activity, and to increase intracellular concentrations of cyclic adenosine monophosphate (cAMP) [11] . In addition to these vasodilator and anti-platelet effects, cilostazol also possesses anti-inflammatory and antioxidant properties [15, 26] . Cilo-stazol showed protective effects against cerebral ischemic injury via inhibition of apoptotic and oxidative cell death [15] .
Interestingly, cilostazol possesses neovascularization effects.
Cilostazol increased the production of hepatocyte growth factor in vascular smooth muscle cells, which enhanced angiogenesis in hind limb ischemia [29] . In addition, increased vasculature post-cilostazol administration was observed in mdx dystrophic skeletal muscle [10] . Cilostazol promoted endothelial nitric oxide production in human aortic endothelial cells, as well as endothelial tube formation [9] . Cilostazol reduced infarct volume and preserved motor and cognitive function in a rat stroke model. These effects were mediated by promoting angiogenesis through pericyte proliferation [24] . Cilostazol has been reported to promote neovascularization and the expression of angiogenic factors in the hippocampus in a mouse forebrain ischemia model [30] . Cilostazol also enhanced integrin-dependent homing of endothelial progenitor cells to sites of ischemia in a forebrain ischemia model [14] . Herein, we investigated which angiogenic mechanisms are regulated by cilostazol by using human brain microvascular endothelial cells.
Materials and Methods
Cell culture and drugs Human brain microvascular endothelial cells (HBMECs;
passages 5-7, ACBRI) were cultured in complete medium [M199 medium containing 20% fetal bovine serum (FBS; Gibco), basic fibroblast growth factor (bFGF; 3 ng/ml; Millipore), heparin (10 U/ml) and 1% penicillin/streptomycin (both from Gibco) [17] ]. Cilostazol (donation from Otsuka Pharmaceutical Co. Ltd) was dissolved in dimethyl sulfoxide (10 mM stock solution). 
In vitro tube formation assay

Cell migration assay
HBMECs were seeded on 60-mm culture dishes and cultured up to 95% confluence. After scratching with a razor blade 5-mm in width, the cultures were washed with serum-free medium twice and further incubated in M199 media containing 1% FBS and 1 mM thymidine. Appropriate 
Verification of gene expression with real-time PCR
The Moloney Murine Leukemia Virus-reverse transcriptase (Promega, Madison, WI, USA) was used to produce cDNA from 2 μg of total RNA according to the manufacturer's recommendations. Real-time PCR was performed using a Rotor-Gene Q real-time PCR system (Qiagen, Düsseldorf, Hilden, Germany) with SYBR Green PCR Master Mix (Qiagen, Düsseldorf, Hilden, Germany) using the primers listed in Table 1 . The results were normalized to 18S rRNA gene expression. All experiments were performed in triplicate and repeated at least three times, and threshold cycles (Ct) were used to quantify the mRNA expression of the target genes.
Western blot analysis
Total protein from HBMECs was isolated as standard techniques, separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred onto a nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ). Primary antibody against PSAT1 (Thermo Fisher scientific Inc., Waltham, USA) was applied to nitrocellulose membrane, followed by secondary antibody conjugated with horseradish peroxidase. Anti-α-tubulin antibody (Sigma, St. Louis, USA) was used as an internal control.
The intensity of chemiluminescence was measured using an ImageQuant LAS 4000 apparatus (GE Healthcare Life Sciences, Uppsala, Sweden). Band intensity was quantified using ImageJ (NIH).
Statics
All data are expressed as the mean ± the standard deviations (SD). The statistical differences between the groups were compared using the unpaired t-test or the one-way analysis of variance (ANOVA). P-values≤0.05 were considered to indicate statistically significant results.
Results
Cilostazol increased brain endothelial migration
Cilostazol has been known to enhance neovascularization after focal ischemia [30] . We observed the effect of cilostazol at each step of the angiogenic mechanism using human brain microvascular endothelial cells (HBMECs). We first conducted a wound migration assay to analyze endothelial motility in response to cilostazol (Fig. 1) . Treatment with cilostazol significantly increased HBMEC migration compared to the control basal medium group in a dose-dependent manner (Fig. 1B) .
Endothelial proliferation and capillary-like tube formation was not affected by cilostazol
We next analyzed the effect of cilostazol on HBMEC proliferation ( Fig. 2A) . In contrast to the migration assay, cilostazol did not enhance HBMEC proliferation compared to basal medium alone. HBMECs cultured in complete medium were used as a positive control, and they showed enhanced proliferation ( Fig. 2A) . We then tested if cilostazol could stimulate vessel-like tube formation in HBMECs (Fig. 2B ). genes up-regulated and 92 genes down-regulated. We searched the roles of these genes in previous reports and selected 5 candidate genes that were known to be possibly involved in cell migration ( Table 2) . We confirmed the candidate gene expression of 2 up-regulated genes (PSAT1, C/ EBPβ) and 3 down-regulated genes (TFPI2, RARRES1 and RARRES3) by real-time PCR (Fig. 3 and Fig. 4 ). In addition, PSAT1 expression was confirmed by western blot analysis, which was upregulated by cilostazol treatment (Fig. 3C ).
Discussion
Endothelial migration is one of the most intensively studied processes in angiogenesis. The migration process is regulated by multiple signaling pathways that can act in a different manner on different blood vessels, and this signaling selectivity is thought to contribute to the modulation of the simultaneous formation of separate blood vessels [31, 33] .
We found that cilostazol treatment stimulated brain endothelial motility (Fig. 1) , and several genes known to be associated with cell migration were modulated by cilostazol: PSAT1 and C/EBPβ were up-regulated and TFPI2, RARRES1 and RARRES3 were down-regulated (Table 2, Fig. 3, Fig. 4 ).
Phosphoserine aminotransferase 1 (PSAT1) is an enzyme involved in serine biosynthesis. PSAT1 has some important metabolic functions such as PSAT1 deficiency results in intractable seizures and acquired microcephaly [8] , and reduced expression in diabetic mice [36] . However, there was no previous information regarding PSAT1 expression and function in endothelial migration. Increased expression of PSAT1 has been reported to be associated with cancer metastasis [19, 27, 34] . PSAT1 overexpression promoted esophageal squamous cell carcinoma metastasis, and PSAT1 stimulates the expression of snail, which has been reported as a key regulator of cell migration and epithelial-mesenchymal transition [13, 19] . In addition, PSAT1 inhibition reduced the invasion and metastasis of cancer cells [34] . From these previous reports, we assumed that cilostazol-mediated PSAT1 up-regulation may have a role in endothelial migration.
Expression of CCAAT/enhancer binding protein β (C/ EBPβ) increases in cilostazol-treated HBMECs (Fig. 3) . C/ EBPβ is a member of a transcription factor family that takes part in the cell migration process [3, 12, 18] . Induction of C/EBPβ in muscle stem cells enhanced their migration and contributed to muscle repair in dystrophic muscle [12] . C/EBPβ is an important mediator in endothelial migration during pathological angiogenesis [18] . In addition, hepatocyte growth factor-mediated motility upregulation of human melanocyte depended on C/EBPβ [3] . Therefore, the upregulation of C/EBPb by cilostazol in HBMECs may play an important role in endothelial migration. Among the down-regulated genes by cilostazol (Fig. 4) , tissue factor pathway inhibitor 2 (TFPI2) has been well characterized to be involved in tumor angiogenesis and progression. Reduced TFPI2 expression correlated with angiogenesis in pancreatic carcinomas [37] , TFPI2 knock-down promoted the migration of glioma cells [7] , and TFPI2 overexpression inhibited the migration of trophoblast cells [38] .
In addition, the overexpression of TFPI2 decreased matrix during metastasis [16, 25] . Another down-regulated gene by cilostazol were retinoic acid receptor responder 1 (RARRES1) and RARRES3 (Fig. 4) . RARRES1 was initially identified as a novel retinoic acid receptor regulated gene [22] , and has been reported as a potential tumor suppressor gene downregulated in tumors [23, 28] . Inhibition of RARRES1 in-creased prostate cancer cell invasion [23] . RARRES3 has been reported to associate with metastasis, suppressing the metastasis of colorectal and breast cancers [21, 32] . Although there is no published data of RARRES1 and RARRES3 in endothelial migration, reports about how reduction of RARRES1 or RARRES3 increased tumor metastasis suggest that reduction of RARRES1 or RARRES3 by cilostazol may be one of the regulatory mechanisms for HBMEC motility stimulation by cilostazol.
Taken together, the expression of the PSAT1, C/EBPβ, TFPI2, RARRES1, and RARRES3 genes modulated by cilostazol treatment in HBMECs may result in increased brain endothelial cell migration ability, thus promoting the angiogenesis process. Thus, the clarification of the cilostazolmodulated molecular mechanisms involving these genes will be helpful for angiogenesis-based therapeutics for the treatment of ischemic diseases.
초록：Cilostazol에 의한 뇌혈관내피세포의 세포이동 증진 효과연구 
